Cataract News and Research

Latest Cataract News and Research

Regeneron receives FDA acceptance for EYLEA injection for treatment of macular edema

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for standard review the Company's supplemental Biologics License Application (sBLA) for EYLEA® (aflibercept) Injection for the treatment of Macular Edema following Branch Retinal Vein Occlusion (BRVO).

26 Feb 2014

Study indicates relationship between multivitamin supplement use and cataract risk in men

Long-term daily multivitamin supplement use may lower cataract risk in men, according to a study of nearly 15,000 male physicians published this month in Ophthalmology, the journal of the American Academy of Ophthalmology

21 Feb 2014

LCA-Vision revenues increase 2.1% to $20.6 million in Q4 2013

LCA-Vision Inc., a leading provider of laser vision correction services under the LasikPlus brand, today announced financial and operating results for the three and 12 months ended December 31, 2013.

18 Feb 2014

Duke University Eye Center ophthalmologist uses ReSure Sealant to perform first cataract surgeries

Terry Kim, MD, Professor of Ophthalmology at Duke University Eye Center, performed the first procedures using the ReSure Sealant on his cataract patients in Durham, North Carolina. The ReSure Sealant is the first FDA-approved sealant for ophthalmic use to seal incisions following cataract surgery.

18 Feb 2014

Nutrition and exercise have significant impact on one's vision

With the New Year comes many resolutions, including resolving to exercise more and eat better. While many individuals understand that nutrition and exercise play an important role in helping to prevent diabetes, obesity, and cardiovascular disorders, not many may be aware that these two elements have a significant impact on one's vision as well. Dr. Sandy T. Feldman, a renowned ophthalmologist and corneal expert at Clearview Eye & Laser Center in San Diego, advises patients to examine their physical fitness and eating habits in order to achieve optimum vision.

11 Feb 2014

SMC accepts ILUVIEN for use within NHS Scotland to treat vision impairment

pSivida Corp., a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that the Scottish Medicines Consortium (SMC) has accepted ILUVIEN for use within the National Health Service Scotland under a simple patient access scheme.

10 Feb 2014

pSivida announces financial results for second quarter 2014

pSivida Corp., a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced financial results for its second quarter ended December 31, 2013.

10 Feb 2014

PowerVision closes first tranche of Series D funding

PowerVision, Inc., a private company developing an accommodating intraocular lens, today announced the closing of the first tranche of its Series D funding round with participation from existing investors Venrock, Johnson & Johnson Development Corp., Medtronic, Advanced Technology Ventures, Lexington Capital and Frazier Healthcare Ventures.

28 Jan 2014

Human visual system can retain plasticity even after extended blindness

Deprivation of vision during critical periods of childhood development has long been thought to result in irreversible vision loss.

28 Jan 2014

FDA grants final approval for Hi-Tech Pharmacal's Bromfenac Ophthalmic Solution ANDA

Hi-Tech Pharmacal Co., Inc., a specialty pharmaceuticals company, announced today that the US Food and Drug Administration, granted final approval for the Company's Abbreviated New Drug Application, for Bromfenac Ophthalmic Solution, 0.09% (Once-A-Day), the generic for ISTA Pharmaceuticals' Bromday ophthalmic solution, 0.09%.

23 Jan 2014

FDA approves Ocular Therapeutix’s ReSure Sealant for ophthalmic use

Ocular Therapeutix announced today it has received approval from the Food and Drug Administration to commercialize the ReSure Sealant in the United States, with an indication for prevention of postoperative fluid egress from incisions with a demonstrated wound leak following cataract surgery.

10 Jan 2014

Carl Zeiss Meditec acquires 100% of shares in Aaren Scientific

Carl Zeiss Meditec AG announces it has acquired, through its subsidiary Carl Zeiss Meditec Inc., 100% of the shares in Aaren Scientific Inc., a US-based manufacturer of intraocular lenses (IOLs). Aaren Scientific, headquartered in Ontario, California, has been manufacturing IOLs for more than two decades. The majority of shares in Aaren Scientific had previously been owned by a private investment company as well as other investors, including the CEO and co-founder of Aaren Scientific, Rick Aguilera, who along with the entire management team will stay on board after the transaction.

8 Jan 2014

Most clinical trials of vitamin supplements have flawed methodology

Most large, clinical trials of vitamin supplements, including some that have concluded they are of no value or even harmful, have a flawed methodology that renders them largely useless in determining the real value of these micronutrients, a new analysis suggests.

31 Dec 2013

Preoperative tests increasing for Medicare patients undergoing cataract surgery, despite lack of benefits

The elimination of extensive routine preoperative tests and consultations represents an area of potentially large health care savings across many disciplines, particularly for low-risk patients being evaluated for cataract surgery. It is also a major theme of the Choosing Wisely campaign from the American Board of Internal Medicine.

28 Dec 2013

FIDELITY project compares surgical treatment of degenerative meniscal tears to placebo surgery

The Finnish Degenerative Meniscal Lesion Study (FIDELITY) compared surgical treatment of degenerative meniscal tears to placebo surgery.

27 Dec 2013

Medical consultation increases for Medicare patients before cataract surgery

Preoperative consultations before cataract surgery became more common for Medicare patients despite no clear guidelines about when to require such a service, hinting at unnecessary use of health care resources, according to a study published by JAMA Internal Medicine, a JAMA Network publication.

24 Dec 2013

FDA accepts Regeneron's EYLEA Injection sBLA for standard review

Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has accepted for standard review the Company's supplemental Biologics License Application for EYLEA (aflibercept) Injection for the treatment of Diabetic Macular Edema.

18 Dec 2013

New findings by UCI, German researchers could aid in saving sight of millions

Groundbreaking new findings by UC Irvine and German chemists about how cataracts form could be used to help prevent the world's leading cause of blindness, which currently affects nearly 20 million people worldwide.

6 Dec 2013

Study shows most corneal transplants have remarkable longevity regardless of donor age

Ten years after a transplant, a cornea from a 71-year-old donor is likely to remain as healthy as a cornea from a donor half that age, and corneas from donors over 71 perform slightly less well but still remain healthy for most transplant recipients, according to a study funded by the National Eye Institute (NEI) and led by the UC Davis Health System Eye Center and the University of Cincinnati Eye Institut

27 Nov 2013

EYLEA Injection gets approval in Japan for treatment of macular edema following CRVO

Regeneron Pharmaceuticals, Inc. today announced that EYLEA (aflibercept) Injection has received approval for the treatment of Macular Edema Following Central Retinal Vein Occlusion from the Japanese Ministry of Health, Labour and Welfare.

22 Nov 2013

Cataract News and Research

Latest Cataract News and Research

Regeneron receives FDA acceptance for EYLEA injection for treatment of macular edema

Study indicates relationship between multivitamin supplement use and cataract risk in men

LCA-Vision revenues increase 2.1% to $20.6 million in Q4 2013

Duke University Eye Center ophthalmologist uses ReSure Sealant to perform first cataract surgeries

Nutrition and exercise have significant impact on one's vision

SMC accepts ILUVIEN for use within NHS Scotland to treat vision impairment

pSivida announces financial results for second quarter 2014

PowerVision closes first tranche of Series D funding

Human visual system can retain plasticity even after extended blindness

FDA grants final approval for Hi-Tech Pharmacal's Bromfenac Ophthalmic Solution ANDA

FDA approves Ocular Therapeutix’s ReSure Sealant for ophthalmic use

Carl Zeiss Meditec acquires 100% of shares in Aaren Scientific

Most clinical trials of vitamin supplements have flawed methodology

Preoperative tests increasing for Medicare patients undergoing cataract surgery, despite lack of benefits

FIDELITY project compares surgical treatment of degenerative meniscal tears to placebo surgery

Medical consultation increases for Medicare patients before cataract surgery

FDA accepts Regeneron's EYLEA Injection sBLA for standard review

New findings by UCI, German researchers could aid in saving sight of millions

Study shows most corneal transplants have remarkable longevity regardless of donor age

EYLEA Injection gets approval in Japan for treatment of macular edema following CRVO

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Cataract News and Research

Latest Cataract News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in